首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Generative Recurrent Networks for De Novo Drug Design
【2h】

Generative Recurrent Networks for De Novo Drug Design

机译:从头设计药物的再生递归网络

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Generative artificial intelligence models present a fresh approach to chemogenomics and de novo drug design, as they provide researchers with the ability to narrow down their search of the chemical space and focus on regions of interest. We present a method for molecular de novo design that utilizes generative recurrent neural networks (RNN) containing long short‐term memory (LSTM) cells. This computational model captured the syntax of molecular representation in terms of SMILES strings with close to perfect accuracy. The learned pattern probabilities can be used for de novo SMILES generation. This molecular design concept eliminates the need for virtual compound library enumeration. By employing transfer learning, we fine‐tuned the RNN′s predictions for specific molecular targets. This approach enables virtual compound design without requiring secondary or external activity prediction, which could introduce error or unwanted bias. The results obtained advocate this generative RNN‐LSTM system for high‐impact use cases, such as low‐data drug discovery, fragment based molecular design, and hit‐to‐lead optimization for diverse drug targets.
机译:生成式人工智能模型为化学基因组学和从头药物设计提供了一种新方法,因为它们为研究人员提供了缩小对化学空间的搜索范围并专注于感兴趣区域的能力。我们提出了一种利用从头产生的递归神经网络(RNN)包含长短期记忆(LSTM)细胞的分子从头设计的方法。该计算模型以SMILES字符串的形式捕获了分子表示的语法,精度接近完美。所学习的模式概率可用于从头生成SMILES。这种分子设计概念消除了对虚拟化合物库枚举的需要。通过采用转移学习,我们微调了RNN对特定分子靶标的预测。这种方法可以进行虚拟化合物设计,而无需进行次要或外部活动预测,否则可能会引入错误或不希望的偏差。获得的结果支持针对高影响力用例的这种生成型RNN-LSTM系统,例如低数据药物发现,基于片段的分子设计以及针对多种药物靶标的先导优化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号